Vicore strengthens its pipeline with the acquisition of novel AT2R agonists and decides on an issue in kind of 142,054 shares
Gothenburg, November 2, 2020 – Vicore Pharma Holding AB (publ) (“Vicore”), a pharmaceutical company dedicated to developing innovative medicines for rare lung disorders, today announces the acquisition of a series of intellectual property rights (IPR) as part of the development of novel angiotensin II type 2 receptor (AT2R) agonists.Vicore, which is developing first-in-class orally available small molecule angiotensin II type 2 receptor (AT2R) agonists, today announces the acquisition of IPR that collectively constitutes a pipeline of novel preclinical-stage AT2R agonists from HaLaCore